Drug development to protozoan diseases

Area of Science:

• Medicinal Chemistry
• Parasitology
• Drug Discovery

Background:

• Protozoan parasite infections cause significant global mortality and morbidity, affecting over 500 million people.
• Current disease control strategies are hampered by challenges in vector and reservoir management, and slow vaccine development.
• Existing anti-protozoan chemotherapy, developed over 50 years ago, suffers from limitations including high cost, poor compliance, drug resistance, low efficacy, and adverse safety profiles.

Purpose of the Study:

• To highlight recent advancements in the discovery of novel anti-protozoan drugs.
• To address the urgent need for new therapeutic agents against protozoan parasitic diseases.
• To provide an overview of developments in anti-protozoan drug discovery.

Main Methods:

• Review of recent research and developments in anti-protozoan drug discovery.
• Focus on novel therapeutic strategies and drug candidates.
• Synthesis of information on the challenges and progress in the field.

Main Results:

• Increased research efforts are being directed towards developing new drugs against protozoan parasites.
• This special issue showcases significant advances in the identification and development of new anti-protozoan agents.
• Emerging strategies aim to overcome the limitations of current therapies.

Conclusions:

• There is a critical need for novel anti-protozoan drugs due to the shortcomings of existing treatments.
• Recent progress indicates a promising future for the development of effective therapies against protozoan parasitic diseases.
• Continued research and development are essential for combating the global burden of these infections.